Adagene (ADAG) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Adagene (ADAG) has outperformed Jyong Biotech (MENS) over the past year, gaining 17.0% versus a loss of 96.9%. Jyong Biotech is the larger company by market cap ($139.9 million vs $138.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | MENS |
|---|---|---|
| Share price | $2.06 | $1.84 |
| Market cap | $138.32M | $139.89M |
| 1-day change | -14.17% | -7.07% |
| YTD return | +8.99% | -53.42% |
| 1-year return | +17.05% | -96.88% |
| 5-year return | -82.60% | — |
| EPS (TTM) | $-0.38 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | — |
| Revenue growth (YoY) | +7332.76% | — |
| Net income (latest FY) | $-17.61M | $-4.67M |
| Operating margin | -279.48% | — |
| Net margin | -229.56% | — |
| 52-week high | $4.85 | $63.00 |
| 52-week low | $1.30 | $1.43 |
| Distance from 52-week high | -57.53% | -97.08% |
| Analyst consensus | none | — |
| Avg. price target upside | +381.07% | — |
| Average volume | 286.63K | 45.46K |
| Shares outstanding | 67.14M | 74.23M |
| Employees | 128 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed MENS by 113.9 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
ADAG vs MENS FAQ
Which is bigger, Adagene or Jyong Biotech?
Jyong Biotech (MENS) is larger, with a market capitalization of $139.89M compared with $138.32M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or MENS?
ADAG returned +17.05% over the past 12 months, compared with -96.88% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.